Animal and human models for sepsis

References

• Freeman BD, Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000; 9: 1651–63.
   PubMed Web of Science ®Google Scholar
• van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis 2001; 1: 165–74.
   PubMedGoogle Scholar
• Wichterman KA, Baue AE, ChaudrySepsis and septic shock — a review of laboratory models and a proposal. J Surg Res 1980; 29: 189–201.
   PubMed Web of Science ®Google Scholar
• Piper RD, Cook DJ, Bone RC, Sibbald WJ. Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996; 24: 2059–70.
   PubMed Web of Science ®Google Scholar
• Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock 1998; 9: 1–11.
   PubMed Web of Science ®Google Scholar
• Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990; 49: 186–96.
   PubMed Web of Science ®Google Scholar
• Zellweger R, Wichmann MW, Ayala A, Stein S, DeMaso CM, Chaudry IH Females in proestrus state maintain splenic immune functions and tolerate sepsis better than males. Crit Care Med 1997; 25: 106–10.
   PubMed Web of Science ®Google Scholar
• Wichmann MW, Zellweger R, DeMaso CM, Ayala A, Chaudry IH Mechanism of immunosuppression in males following trauma-hemorrhage. Critical role of testosterone. Arch Surg 1996; 131: 1186–91; discussion 91-2.
   PubMed Web of Science ®Google Scholar
• Deitch EA, Ma L, Ma JW, Berg RD. Lethal burn-induced bacterial translocation: role of genetic resistance. J Trauma 1989; 29: 1480–7.
   PubMedGoogle Scholar
• Porat R, Mosseri R, Kaplan E, Johns MA, Shibolet S. Distribution of polysaccharide side chains of lipopolysaccharide determine resistance of Escherichia coli to the bactericidal activity of serum. J Infect Dis 1992; 165: 953–6.
   PubMed Web of Science ®Google Scholar
• Cross AS, Opal SM, Sadoff JC, Gemski P. Choice of bacteria in animal models of sepsis. Infect Immun 1993; 61: 2741–7.
   PubMed Web of Science ®Google Scholar
• Fink MP, Morrissey PE, Stein KL, Clement RE, Fiallo V, Gardiner WM. Systemic and regional hemodynamic effects of cyclo-oxygenase and thromboxane synthetase inhibition in normal and hyperdynamic endotoxemic rabbits. Circ Shock 1988; 26: 41–57.
   PubMedGoogle Scholar
• Fink MP, Cohn SM, Lee PC, Rothschild HR, Deniz YF, Wang H, et al. Effect of lipopolysaccharide on intestinal intramucosal hydrogen ion concentration in pigs: evidence of gut ischemia in a normodynamic model of septic shock. Crit Care Med 1989; 17: 641–6.
   PubMedGoogle Scholar
• Breslow MJ, Miller CF, Parker SD, Wahnan AT, Traystman RI Effect of vasopressors on organ blood flow during endotoxin shock in pigs. Am J Physiol 1987; 252: H291–300.
   PubMed Web of Science ®Google Scholar
• Emerson TE, Jr., Gill CC. Effects of slow intravenous endotoxin infusion on hemodynamics and survival in dogs. J Appl Physiol 1967; 22: 874–7.
   PubMed Web of Science ®Google Scholar
• Fish RE, Spitzer JA. Continuous infusion of endotoxin from an osmotic pump in the conscious, unrestrained rat: a unique model of chronic endotoxemia. Circ Shock 1984; 12: 135–49.
   PubMedGoogle Scholar
• Fish RE, Burns AH, Lang CH, Spitzer JA. Myocardial dysfunction in a nonlethal, nonshock model of chronic endotoxemia. Circ Shock 1985; 16: 241–52.
   PubMedGoogle Scholar
• Fish RE, Lang CH, Spitzer JA. Regional blood flow during continuous low-dose endotoxin infusion. Circ Shock 1986; 18: 267–75.
   PubMedGoogle Scholar
• Kurtz HJ, Quast J. Effects of continuous intravenous infusion of Escherichia coli endotoxin into swine. Am J Vet Res 1982; 43: 262–8.
   PubMedGoogle Scholar
• Fink Mg Fiallo V, Stein KL, Gardiner WM. Systemic and regional hemodynamic changes after intraperitoneal endotoxin in rabbits: development of a new model of the clinical syndrome of hyperdynamic sepsis. Circ Shock 1987; 22: 73–81.
   PubMedGoogle Scholar
• van der Poll T, van Deventer Sj. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999; 13: 413–26, ix.
   PubMed Web of Science ®Google Scholar
• van der Poll T, van Deventer SJH. Endotoxemia in healthy subjects as a human model of inflammation. In: Cohen J, Marshall J, eds. The immune response in the critically ill. Springer Verlag; 1999: 335–57.
   Google Scholar
• van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520–6.
   PubMed Web of Science ®Google Scholar
• Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA, Jr., Cerami A, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147–53.
   PubMedGoogle Scholar
• Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, et al. Detection of circulating tumor necrosis factor after endotoxin administration N Engl J Med 1988; 318: 1481–6.
   Google Scholar
• Preas HL, 2nd, Reda D, Tropea M, Vandivier RW, Banks SM, Agosti JM, et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 1996; 88: 2465–72.
   PubMed Web of Science ®Google Scholar
• Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995; 155: 5038–45.
   Google Scholar
• Martich GD, Parker MM, Cunnion RE, Suffredini AF. Effects of ibuprofen and pentoxifylline on the cardiovascular response of normal humans to endotoxin. J Appl Physiol 1992; 73: 925–31.
   PubMedGoogle Scholar
• de Winter RJ, von der Mohlen MA, van Lieshout H, Wedel N, Nelson B, Friedmann N, et al. Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans. J Inflamm 1995; 45: 193–206.
   PubMedGoogle Scholar
• Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993; 328: 1457–60.
   PubMedGoogle Scholar
• Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 1991; 51: 2524–30.
   PubMed Web of Science ®Google Scholar
• Engelhardt R, Mackensen A, Galanos C, Andreesen R. Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod 1990; 9: 480–91.
   PubMedGoogle Scholar
• Richardson RP, Rhyne CD, Fong Y, Hesse DG, Tracey KJ, Marano MA, et al. Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects. Influence of elicited hormones and cytokines. Ann Surg 1989; 210: 239–45.
   PubMed Web of Science ®Google Scholar
• Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165–72.
   PubMed Web of Science ®Google Scholar
• Spinas GA, Bloesch D, Keller U, Zimmerli W, Cammisuli S. Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia. J Infect Dis 1991; 163: 89–95.
   PubMed Web of Science ®Google Scholar
• von der Mohlen MA, van der Poll T, Jansen J, Levi M, van Deventer SJ. Release of bactericidal/permeability-increasing protein in experimental endotoxemia and clinical sepsis. Role of tumor necrosis factor. J Immunol 1996; 156: 4969–73.
   PubMedGoogle Scholar
• Moore FD, Jr., Moss NA, Revhaug A, Wihnore D, Marmick JA, Rodrick ML. A single dose of endotoxin activates neutrophils without activating complement. Surgery 1987; 102: 200–5.
   PubMedGoogle Scholar
• Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912–8.
   PubMed Web of Science ®Google Scholar
• Schultz MJ, Knapp S, van der Poll T. Regulatory role of alveolar macrophages and cytokines in pulmonary host defense. In: Vincent JL, ed. Yearbook of Intensive Care and Emergency Medicine 2002. Springer Verlag; 2002: 65–76.
   Google Scholar
• Mehrad B, Standiford TJ. Role of cytokines in pulmonary antimicrobial host defense. Immunol Res 1999; 20: 15–27.
   PubMed Web of Science ®Google Scholar
• Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford T J. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995; 155: 722–9.
   Google Scholar
• Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 1997; 159: 2858–66.
   Google Scholar
• Skerrett SJ, Martin TR, Chi EY, Peschon JJ, Mohler KM, Wilson CB. Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa. Am J Physiol 1999; 276: L715–27.
   Google Scholar
• van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996; 174: 994–1000.
   PubMed Web of Science ®Google Scholar
• van der Poll T, Keogh CV, Bunrman WA, Lowry SF. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997; 155: 603–8.
   Google Scholar
• Schultz MJ, Rijneveld AW, Speelman P, Deventer SJ, van der Poll T. Endogenous interferon-gamma impairs bacterial clearance from lungs during Pseudomonas aeruginosa pneumonia. Eur Cytokine Netw 2001; 12: 39–44.
   PubMedGoogle Scholar
• Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, van der Poll T. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2002; 282: L285–90.
   PubMedGoogle Scholar
• Ahrenholz DH, Simmons RL. Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 1980; 88: 41–7.
   PubMed Web of Science ®Google Scholar
• Natanson C, Fink MP, Ballantyne HK, MacVittie Conklin JJ, Parrillo JE. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 1986; 78: 259–70.
   PubMedGoogle Scholar
• Fink MP, MacVittie TJ, Casey LC. Inhibition of prostaglandin synthesis restores normal hemodynamics in canine hyperdynamic sepsis. Ann Surg 1984; 200: 619–26.
   PubMedGoogle Scholar
• Sewnath ME, Olszyna DP, Birjmohun R, ten Kate FJ, Gouma DJ, van der Poll T. IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 2001; 166: 6323–31.
   PubMed Web of Science ®Google Scholar
• Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163: 83–8.
   PubMed Web of Science ®Google Scholar
• Evans GF, Snyder YM, Butler LD, Zuckerman SH. Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ Shock 1989; 29: 279–90.
   PubMedGoogle Scholar
• Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol 1992; 148: 1890–7.
   PubMed Web of Science ®Google Scholar
• Marchant A, Bruyns C, Vandenabeele P, Abramowicz D, Gerard C, Delvaux A, et al. The protective role of interleukin-10 in endotoxin shock. Prog Clin Biol Res 1994; 388: 417–23.
   PubMedGoogle Scholar
• Hinshaw LB, Beller-Todd BK, Archer LT, Benjamin B, Flournoy DJ, Passey R, et al. Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli. Ann Surg 1981; 194: 51–6.
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNE monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–4.
   PubMed Web of Science ®Google Scholar
• The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317: 659–65.
   PubMed Web of Science ®Google Scholar
• Abraham E, Wunderink R, Silverman H, Pert TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934–41.
   PubMed Web of Science ®Google Scholar
• Bone RC, Fisher CJ, Jr., Clemmer TP, Slotrnan GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl I Med 1987; 317: 653–8.
   PubMed Web of Science ®Google Scholar
• Moore KW, A OG, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11: 165–90.
   PubMed Web of Science ®Google Scholar
• Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford T J. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect lmmun 1996; 64: 5211–8.
   PubMed Web of Science ®Google Scholar
• Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599–605.
   PubMed Web of Science ®Google Scholar